Management of Antidiabetic Therapy in Patients Undergoing [18F]FDG PET
DOI:
https://doi.org/10.20344/amp.24274Keywords:
Diabetes Mellitus/drug therapy, Fluorodeoxyglucose F18, Guidelines as Topic, Positron Emission Tomography, Positron Emission Tomography Computed TomographyAbstract
Positron emission tomography (PET) with fluorodeoxyglucose {[18F]FDG} is a technique used to identify areas of increased glycolytic metabolism, aiding in the diagnosis, staging, and follow-up of neoplastic, infectious, or inflammatory disease. In people with diabetes mellitus (DM), hyperglycemia and hyperinsulinemia alter the radiotracer biodistribution, compromising the diagnostic accuracy of this test. The absence of clear guidelines may result in inadequate patient preparation and the need to postpone or repeat the test, causing harm to the patient and the institution. This clinical practice guideline results from a review of available evidence and a multidisciplinary consensus process between the Endocrinology and Nuclear Medicine services of Unidade Local de Saúde São João, aiming to establish recommendations applicable to the Portuguese hospital context. The document includes detailed recommendations on the management of antidiabetic drugs before performing [18F]FDG PET, organized by specific clinical scenarios: 1) type 2 DM; 2) type 1 DM, including patients with continuous subcutaneous insulin infusion systems; and 3) diabetes secondary to corticosteroid therapy. In case of hyperglycemia between 200 - 350 mg/dL on the day of the test, the guideline includes the administration of insulin according to a personalized scheme, adapted to body mass index and renal function. The implementation of this guideline aims to standardize the preparation of people with diabetes for [18F]FDG PET and minimize the need to postpone or repeat tests, allowing for the optimization of hospital resource management.
Downloads
References
Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328-54. DOI: https://doi.org/10.1007/s00259-014-2961-x
Surasi DS, Bhambhvani P, Baldwin JA, Almodovar SE, O’Malley JP. 18F-FDG PET and PET/CT patient preparation: a review of the literature. J Nucl Med Technol. 2014;42:5-13. DOI: https://doi.org/10.2967/jnmt.113.132621
Rallapeta R, Manthri RG, Kalawat T, Sachan A, Lakshmi AY, Hulikal N. Utility of short-acting intravenous insulin therapy in preparation of F-18 fluorodeoxyglucose positron emission tomography computed tomography scan in cancer patients incidentally detected with high blood glucose levels on the day of test. Indian J Nucl Med. 2020;35:110-5. DOI: https://doi.org/10.4103/ijnm.IJNM_151_19
Garcia J, Sanchis A, Juan J, Tomas J, Domenech A, Soler M, et al. Influence of subcutaneous administration of rapid-acting insulin in the quality of 18F-FDG PET/CT studies. Nucl Med Commun. 2014;35:459-65. DOI: https://doi.org/10.1097/MNM.0000000000000082
Hernández Grimaldo EG. Impacto de la terapia intravenosa con insulina de corta acción en la biodistribución del 18F-FDG en PET/CT de pacientes con hiperglucemia detectada incidentalmente. Nuevo León: Universidad Autónoma de Nuevo León; 2023.
Pattison DA, Hicks RJ, Macfarlane DJ, Lasubika SM, Hogg A, Akhurst TJ, et al. Personalised insulin calculator enables safe and effective correction of hyperglycaemia prior to FDG PET/CT. EJNMMI Res. 2019;9:15. DOI: https://doi.org/10.1186/s13550-019-0480-2
Roy FN. Impact of intravenous insulin on 18F-FDG PET in diabetic cancer patients. J Nucl Med. 2009;50:178-83. DOI: https://doi.org/10.2967/jnumed.108.056283
Duarte DS, Violante L, Torres I, Duarte H. Tomografia por emissão de positrões com [18F]-FDG e diabetes mellitus – protocolo de abordagem. Acta Radiol Port. 2021;33:19-24.
Seth S, Gallagher EJ. Optimal management of insulin in patients undergoing 18F-fluorodeoxyglucose positron emission tomography scans. Endocr Pract. 2023;29:705-9. DOI: https://doi.org/10.1016/j.eprac.2023.06.006
Taïeb D, Hicks RJ, Hindié E, Guillet BA, Avram A, Ghedini P, et al. European association of nuclear medicine practice guideline/society of nuclear medicine and molecular imaging procedure standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging. 2019;46:2112-37. DOI: https://doi.org/10.1007/s00259-019-04398-1
Matievich W, Kiaie N, Dunn TC. Safety and functional integrity of continuous glucose monitoring sensors when used during radiologic procedures under high exposure conditions. J Diabetes Sci Technol. 2023;17:1634-43. DOI: https://doi.org/10.1177/19322968221106206
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Acta Médica Portuguesa
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All the articles published in the AMP are open access and comply with the requirements of funding agencies or academic institutions. The AMP is governed by the terms of the Creative Commons ‘Attribution – Non-Commercial Use - (CC-BY-NC)’ license, regarding the use by third parties.
It is the author’s responsibility to obtain approval for the reproduction of figures, tables, etc. from other publications.
Upon acceptance of an article for publication, the authors will be asked to complete the ICMJE “Copyright Liability and Copyright Sharing Statement “(http://www.actamedicaportuguesa.com/info/AMP-NormasPublicacao.pdf) and the “Declaration of Potential Conflicts of Interest” (http:// www.icmje.org/conflicts-of-interest). An e-mail will be sent to the corresponding author to acknowledge receipt of the manuscript.
After publication, the authors are authorised to make their articles available in repositories of their institutions of origin, as long as they always mention where they were published and according to the Creative Commons license.
